Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$66.82-1.87%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · BMY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks BMY against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on expanding revenues from the Growth Portfolio medicines early in their lifecycles to achieve sustainable long-term growth.
Stated as a priority in 6 of last 6 quarters. Growth Portfolio revenues grew from $5.6B in 2025-Q1 to $7.6B in 2026-Q2, representing consistent double-digit growth each quarter. Management has reiterated focus on this portfolio as the main growth driver, and the trajectory is delivering.
“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter.”
“Growth Portfolio revenues increased 12%, or 9% Ex-FX.”
“Growth Portfolio revenues increased 16%, or 15% Ex-FX.”
“Growth Portfolio revenues increased 18%, or 17% Ex-FX.”
“Growth Portfolio revenues increased 18%, or 17% Ex-FX.”
“Growth Portfolio revenues increased 16%, or 18% Ex-FX.”
Continue disciplined capital allocation to support sustainable cash flow generation, balance sheet strength, and long-term shareholder returns.
Stated as a priority in 6 of last 6 quarters. Operating cash flow remained strong, with quarterly cash from operations around $1.95B to $1.97B in 2025 and $1.1B to $2.0B in early 2026. Net income showed improvement from $1.1B in 2025-Q4 to $2.7B in 2026-Q1. Management consistently emphasizes disciplined capital allocation, and financials show stable cash flow supporting this priority.
Focus R&D on developing high-impact, transformational medicines to treat life-threatening diseases and progress pipeline candidates.
Stated as a priority in 6 of last 6 quarters. R&D expenses increased from approximately $9.5B in 2024 to $9.8B in 2025, and quarterly R&D rose 15% from $2.58B in 2025-Q2 to $2.96B in 2026-Q2. Management consistently emphasizes focus on transformational medicines, and financials show increased investment supporting this priority.
Maintain disciplined cost management to sustain gross margin percentage in the range of approximately 69% to 70%.
Stated as a priority in 4 of last 4 quarters. Gross margin on a GAAP basis was 70.2% in 2026-Q1 and 71.3% in 2026-Q2, slightly above the 69%-70% guidance range. Management has consistently maintained this gross margin target, and the actual margins show stable to slightly improving performance, delivering on this priority.
“Gross Margin % ~69% - 70% reaffirmed in guidance.”
Increase full-year 2026 revenue guidance to approximately $49.0B-$50.0B and non-GAAP EPS guidance to $6.75-$7.00.
Newly stated in 2026-Q2 and reaffirmed in 2026-Q1. Management raised full-year 2026 revenue guidance from approximately $46.0-$47.5 billion to $49.0-$50.0 billion and increased non-GAAP EPS guidance from $6.05-$6.35 to $6.75-$7.00. This reflects broad-based momentum across the portfolio and aligns with recent quarterly revenue growth trends, indicating delivery on this updated guidance.
“Raising 2026 revenue guidance to a range of ~$49.0 billion to $50.0 billion; Increasing non-GAAP EPS range to $6.75 to $7.00.”
Over the trailing year it converted -2.02x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“Maintaining disciplined capital allocation to drive sustainable cash flow generation, balance sheet strength and long-term shareholder returns.”
“Maintaining disciplined capital allocation to drive sustainable cash flow generation, balance sheet strength and long-term shareholder returns.”
“Maintaining disciplined capital allocation to drive sustainable cash flow generation, balance sheet strength and long-term shareholder returns.”
“Maintaining disciplined capital allocation to drive sustainable cash flow generation, balance sheet strength and long-term shareholder returns.”
“Maintaining disciplined capital allocation to drive sustainable cash flow generation, balance sheet strength and long-term shareholder returns.”
“Maintaining disciplined capital allocation to drive sustainable cash flow generation, balance sheet strength and long-term shareholder returns.”
“Focusing R&D on high-impact, transformational medicines to treat life-threatening diseases.”
“Focusing R&D on high-impact, transformational medicines to treat life-threatening diseases.”
“Focusing R&D on high-impact, transformational medicines to treat life-threatening diseases.”
“Focusing R&D on high-impact, transformational medicines to treat life-threatening diseases.”
“Focusing R&D on high-impact, transformational medicines to treat life-threatening diseases.”
“Focusing R&D on high-impact, transformational medicines to treat life-threatening diseases.”
“Gross Margin % ~69% - 70% reaffirmed in guidance.”
“Gross Margin % ~69% - 70% reaffirmed in guidance.”
“Gross Margin % ~69% - 70% reaffirmed in guidance.”
“Reaffirms 2026 financial guidance with total revenues and diluted EPS trending toward the upper end of the ranges.”